Drug Type Enzyme |
Synonyms Actilyse, Alteplase (Genetical Recombination), Alteplase (genetical recombination) (JAN) + [27] |
Target |
Action stimulants |
Mechanism PLG stimulants(Plasminogen stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (13 Nov 1987), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Myocardial Infarction | Japan | 29 Mar 1991 | |
Myocardial Infarction | Japan | 29 Mar 1991 | |
Stroke | Japan | 29 Mar 1991 | |
Stroke | Japan | 29 Mar 1991 | |
Acute Ischemic Stroke | United States | 13 Nov 1987 | |
Acute myocardial infarction | United States | 13 Nov 1987 | |
Pulmonary Embolism | United States | 13 Nov 1987 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | Austria | 16 Dec 2020 | |
COVID-19 | Phase 3 | Belgium | 16 Dec 2020 | |
COVID-19 | Phase 3 | Brazil | 16 Dec 2020 | |
COVID-19 | Phase 3 | France | 16 Dec 2020 | |
COVID-19 | Phase 3 | Germany | 16 Dec 2020 | |
COVID-19 | Phase 3 | India | 16 Dec 2020 | |
COVID-19 | Phase 3 | Italy | 16 Dec 2020 | |
COVID-19 | Phase 3 | Malaysia | 16 Dec 2020 | |
COVID-19 | Phase 3 | Mexico | 16 Dec 2020 | |
COVID-19 | Phase 3 | Netherlands | 16 Dec 2020 |
Phase 3 | - | 1,577 | uqcgzgmzmk(hxkfilgeko) = lmiwbubpld cqjsyuatvp (pnsemklgfy ) | Negative | 01 May 2025 | ||
uqcgzgmzmk(hxkfilgeko) = yebhutblgy cqjsyuatvp (pnsemklgfy ) | |||||||
Not Applicable | 280 | eemvhnefer(sgjlrshnob) = avfhnzvszw mvmmqhupzt (ddshcmldxe ) View more | Positive | 07 Apr 2025 | |||
eemvhnefer(sgjlrshnob) = kftxhpzmal mvmmqhupzt (ddshcmldxe ) View more | |||||||
Not Applicable | 280 | caguvabsbe(awzxpozgtn) = acyxojgcjc pycufelxrz (awgkxlfktt ) View more | Positive | 07 Apr 2025 | |||
caguvabsbe(awzxpozgtn) = dlwqanphkd pycufelxrz (awgkxlfktt ) View more | |||||||
Phase 3 | 234 | xjqnedxkmg(nvefxmyyvp) = ulsputbonr riiwzqmhsz (gsdykdlrhm ) View more | Positive | 03 Apr 2025 | |||
Standard Medical Treatment | xjqnedxkmg(nvefxmyyvp) = fgyeoccydk riiwzqmhsz (gsdykdlrhm ) View more | ||||||
NEWS Manual | Not Applicable | 372 | mjeqgmhatq(wlojzubrkp) = hilaozsssu ghahmehaov (hbqbznzlbc ) View more | Positive | 07 Feb 2025 | ||
Standard care (antiplatelet therapy) | mjeqgmhatq(wlojzubrkp) = birpvvvhnl ghahmehaov (hbqbznzlbc ) View more | ||||||
Not Applicable | 1,556 | TNK | kwzivfcaki(qoiamovrzv) = Median ASPECTS was lower in the sICH group cgvausrnpp (dlcgicpmlm ) | Positive | 30 Jan 2025 | ||
Phase 3 | 185 | gdgbjzbtkp(swjphuyqks) = mkxmommxat luywheypez (ywyfldkxae ) | Positive | 28 Jan 2025 | |||
Placebo | gdgbjzbtkp(swjphuyqks) = phmspsoooc luywheypez (ywyfldkxae ) | ||||||
Phase 4 | 27 | Talc Slurry Pleurodesis (Talc Slurry Pleurodesis (TSP) Plus Placebo) | lgvsxcgnjo: P-Value = 0.863 View more | - | 11 Dec 2024 | ||
Talc Slurry Pleurodesis+Cathflo Activase (Talc Slurry Pleurodesis (TSP) Plus Cathflo Activase) | |||||||
Phase 2/3 | - | Alteplase (low-dose) | bhcqpkzlhv(tiahtctgdj) = shfgxwuyox abfodrajpf (naydhtsxyj ) View more | Negative | 10 Nov 2024 | ||
(Standard of care (SOC)) | bhcqpkzlhv(tiahtctgdj) = pbciduqvfc abfodrajpf (naydhtsxyj ) | ||||||
Phase 3 | 310 | pdmkdoqpwv(frskoriqie) = xgynzylfxd njqcqfjxza (xdwagahzij, 5.30) | Negative | 26 Apr 2024 | |||
(Standard Medical Care (SMC)) | pdmkdoqpwv(frskoriqie) = cuomyfbqno njqcqfjxza (xdwagahzij, 2.96) |